e-Fund completes investment in MesentechMay 24th, 2019
e-Fund, a British Columbia Venture Capital Corporation (VCC), closed its investment in Mesentech on 24th May 2019. This investment will enable Mesentech to initiate safety trials of a candidate conjugate drug for reversing bone-loss.
Merck Invention Accelerator Welcomes MesentechMay 7th, 2019
Mesentech has won a coveted position at the Merck Invention Accelerator in partnership with the University of Alberta. Merck launched the first Invention Accelerator in Edmonton at the end of 2018. The program consists of non-dilutive funding, lab space, and mentorship from Merck's team team on business and clinical development. This relationship does not require any equity or commercial rights from Mesentech.
Dr. Roland Baron joins Mesentech's Scientific Advisory BoardApr 30, 2019
Dr. Roland Baron, is a professor at the Harvard Medical School, Massachusetts General Hospital, and chair of oral medicine at the Harvard School of Dental Medicine. Formerly, Dr Baron was professor of orthopedics and cell biology at Yale University School of Medicine and editor-in-chief of the Journal of the International Bone and Mineral Society. Between 1994 and 2002 was vice-president and head of the bone diseases group at Hoechst Marion Roussel and then Aventis. Prof. Baron has published over 300 scientific papers in the field of bone biology and bone diseases.
Mesentech Drug C3 will be tested aboard International Space StationApr 8, 2019
The ISS National Lab will be testing Mesentech's bone-anabolic compounds on the International Space Station for their potential to reverse osteoporosis related to weightlessness in space. This research is being being conducted with the support of the Center for the Advancement of Science in Space in collaboration with Houston Methodist Hospital. Tentative launch date is July 8th from Kennedy Space Center in Florida aboard a SpaceX Dragon.
Dr. David Thompson joins Mesentech SABMar 26, 2019
Dr. Thompson is a former executive of Alexion where he was global leader of the asfotase alfa (Stensiq) program for the treatment of hypophosphatasia. Previously he was Executive Vice-President at Pfizer where he developed and commercialized lasofoxifene (Fablyn). Dr. Thompson started his career at Merck under the leadership of Gideon Rodan where he developed and commercialized Fosamax.
Canadian patent covering conjugate drugs grantedMar 19, 2019
Intellectual property covering the new chemical entities for bone targeting conjugate drugs was granted by Canadian Intellectual Property Office. Expiration in 2031
Mesentech candidate drug C3 used in peer-reviewed article published by Journal of Oral & Maxillofacial ImplantsMar 13, 2019
One of Mesentech's candidate drugs, C3, was used in a new biomaterial. Experimenters at Mount Sinai hospital used a brushite or monetite base with or without C3 implanted onto rabbit calvaria. The grafts containing C3 integrated with new bone extending 80% through the graft area while the C3 lacking grafts showed decreased surface integration of 38%. Moreover, C3 containing grafts had 2.7mm vertical bone augmentation compared to nil for C3 deficient grafts. The advantages of this new graft drug formulation in future would be to provide more predictable vertical bone regeneration, which will ultimately benefit patients undergoing dental implant placement.
WUTIF closes investment in MesentechMar 12, 2019
WUTIF (pronounced "what if) a British Columbia Venture Capital Corporation closed an investment in Mesentech.
Mesentech named "Emerging Rocket" Mar 11, 2019
Mesentech has been selected as an "Emerging Rocket" by Rocket Builders
“We identify companies that have both innovative technology and a fit within the industry value chain. Our analysis of the market and the company progress led to our selection of Mesentech as an Emerging Rocket Life Science company.” said Thealzel Lee, Senior Partner, Rocket Builders.
About Ready to Rocket Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top private companies that are best positioned to capitalize on these trends to achieve growth. This selection methodology has been an accurate predictor of investment and business success with past "Ready to Rocket" companies. http://www.readytorocket.com
Mesentech drugs used in development of new anabolic-biomaterials at the University of TorontoMar 4, 2019
Researchers at the University of Toronto are incorporating Mesentech's bone-specific drugs to create a new anabolic-bone-biomaterial for surgical indications with the hope crating a stronger more natural bone much faster than currently available techniques.
Mesentech is attending JP Morgan Healthcare ConferenceJan 6-11, 2019San Francisco, CA USA
Please email info [ at @] mesentech.com to request a meeting
CCRM completes investment in MesentechJan 1, 2019
Center for the Commercialization of Regenerative Medicine completed an investment in Mesentech at the close of 2018.
WSGR invites Mesentech to present at Healthcare Investment ForumNovember 6-9, 2018Palo Alto, CA USA
Wilson Sonsini Goodrich & Rosati's Healthcare Investment Forum presents an opportunity for life sciences venture investment firms to connect with promising start-ups to discuss potential funding. WSGR is the premier provider of legal services to technology, life sciences, and growth enterprises worldwide.
European Patent #EP2576575B1 GrantedSept 5, 2018
“Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof” granted 2018-09-05 (Patent is owned by SFU and licensed exclusively to Mesentech Inc.)
Clinical note published by Mesentech KOLs Drs. Sheikh & GlogauerJuly 23, 2018
American Academy of Implant Dentistry publishes clinical note (The Challenge of Predictable Vertical Alveolar Ridge Augmentation for Dental Implant Site Development) summarizing original research by Drs. Sheikh and Glogauer who won first place at the poster competition held at the American Academy of Implant Dentistry (AAID) 66th Annual Conference in San Diego. Full AAID summer issue.
Patent for "C3" US20180170951A1 PublishedJune 21, 2018
Third conjugate anabolic molecule, "C3," structure published. Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof (Patent is owned by SFU and licensed exclusively to Mesentech Inc.)
1st Place finisher at American Association for Implant Dentistry 66th Annual Conference October 11-14, 2017San Diego, CA USA
Drs Sheikh and Glogauer won first place at 66th annual AAID conference in San Diego for poster describing original research using Mesentech's novel bone-anabolic conjugates
US Patent for "C1" US9650414B1 GrantedMay 16, 2017
US Patent #9650414 “New classes of EP4 conjugate compounds -II; Dual Function Bone-targeting Peptide linked Pro-drugs” granted 2017-05-16 (Patent is owned by SFU and licensed exclusively to Mesentech Inc.)